RNA Editing for Inherited Disorders: Mechanisms, Clinical Applications, and Future Directions

Abstract

RNA editing is an emerging molecular technology with the potential to revolutionize the treatment of inherited disorders by correcting pathogenic mutations at the RNA level. Unlike conventional gene therapy targeting DNA, RNA editing offers a transient, potentially safer, and more controllable alternative for rectifying genetic defects. This review synthesizes current scientific evidence on RNA editing mechanisms, clinical relevance in inherited disorders, recent therapeutic advances, and expert perspectives on its translational potential, with a focus on academic rigor and practical implications for healthcare professionals.

Introduction

Inherited disorders, resulting from pathogenic gene mutations, pose significant diagnostic and therapeutic challenges in clinical medicine. With the increasing understanding of molecular genetics and advancements in genome manipulation technologies, RNA editing has emerged as a promising approach for targeted correction of disease-causing mutations. Unlike permanent DNA modifications, RNA editing modifies the transcriptome, offering precision and reversibility in genetic interventions. This review aims to provide a comprehensive and clinically relevant overview of RNA editing, focusing on its mechanisms, applications in inherited disorders, and future prospects in precision medicine.

Epidemiology / Disease Burden

Monogenic inherited disorders affect millions of individuals worldwide, with an estimated global incidence of 10 in 1,000 live births for single-gene diseases. Conditions such as cystic fibrosis, Duchenne muscular dystrophy, and various hemoglobinopathies contribute significantly to morbidity, mortality, and healthcare burden. The lack of curative treatments for many of these disorders underscores the urgent need for innovative therapies. RNA editing offers the potential to address this unmet need, particularly for disorders where traditional gene therapy is limited by delivery challenges, immunogenicity, or off-target effects.

Pathophysiology

The pathogenesis of inherited disorders is rooted in mutations that alter the coding sequence of genes, resulting in defective or absent proteins. RNA editing technologies, such as adenosine-to-inosine (A-to-I) and cytidine-to-uridine (C-to-U) editing, harness endogenous or engineered enzymes to correct pathogenic transcripts post-transcriptionally. By targeting mRNA, RNA editing can restore normal protein function without altering the germline, reducing the risk of unintended heritable changes. For example, ADAR (adenosine deaminase acting on RNA)-mediated editing can recode premature stop codons or missense mutations, thereby rescuing protein function in diseases like Rett syndrome or certain muscular dystrophies.

Risk Factors

While the risk factors for inherited disorders are primarily genetic, the implementation of RNA editing therapies introduces unique considerations. Potential risks include off-target editing, immune responses to delivery vectors or editing enzymes, and incomplete or mosaic correction of target transcripts. Patient-specific factors such as mutation type, tissue accessibility, and disease stage also influence the feasibility and efficacy of RNA editing interventions. Careful patient selection, robust preclinical validation, and long-term follow-up are critical components in mitigating these risks in clinical settings.

Clinical Features

Inherited disorders manifest with a spectrum of clinical features depending on the affected gene, mutation type, and tissue involvement. For example, cystic fibrosis presents with pulmonary and gastrointestinal symptoms, while spinal muscular atrophy leads to progressive neuromuscular weakness. The clinical relevance of RNA editing lies in its potential to restore or partially restore function in affected tissues, offering symptomatic relief or disease modification. Early-phase clinical trials and preclinical models have demonstrated reversal of disease phenotypes following successful RNA editing, supporting its translational promise.

Diagnosis

Accurate molecular diagnosis is essential for identifying candidates for RNA editing therapies. Next-generation sequencing, targeted gene panels, and transcriptomic analyses enable precise characterization of causative mutations and their transcriptomic consequences. Additionally, quantification of RNA editing efficiency and specificity in patient-derived cells is crucial for predicting therapeutic outcomes and monitoring treatment responses. Ongoing advancements in single-cell RNA sequencing and digital PCR further enhance diagnostic precision and patient stratification for RNA editing trials.

Treatment & Management

Current treatment options for inherited disorders are often limited to supportive care, symptomatic management, or enzyme replacement therapies. RNA editing introduces a new paradigm by enabling correction of pathogenic transcripts at the RNA level. Therapeutic strategies include in vivo delivery of guide RNAs and editing enzymes using lipid nanoparticles or viral vectors, as well as ex vivo editing of patient-derived cells followed by autologous transplantation. Clinical management requires multidisciplinary collaboration, careful monitoring for adverse effects, and integration with standard of care protocols to optimize patient outcomes.

Recent Advances / Emerging Therapies

Recent years have witnessed significant progress in the development of RNA editing tools, including engineered ADAR enzymes, programmable RNA-guided systems, and base editors with improved specificity and efficiency. Preclinical studies have demonstrated successful correction of disease-causing mutations in models of ornithine transcarbamylase deficiency, alpha-1 antitrypsin deficiency, and Dravet syndrome. Early-phase clinical trials are underway for selected indications, with promising safety and efficacy profiles reported to date. The integration of RNA editing with other therapeutic modalities, such as antisense oligonucleotides and small molecules, may further expand its clinical utility.

Guideline Recommendations

While formal clinical guidelines for RNA editing are still evolving, expert consensus emphasizes the importance of rigorous preclinical validation, standardized outcome measures, and ethical considerations in trial design. Regulatory agencies advocate for comprehensive safety assessments, transparent reporting of off-target effects, and long-term surveillance of treated patients. Multidisciplinary input from geneticists, molecular biologists, clinicians, and bioethicists is vital for establishing best practices and ensuring responsible translation of RNA editing technologies into clinical care.

Conclusion

RNA editing represents a transformative advance in the precision treatment of inherited disorders, offering targeted, reversible, and potentially safer alternatives to DNA-based genome editing. Although still in early stages, clinical translation is progressing rapidly, supported by robust preclinical data and early human studies. Continued innovation in editing tools, delivery systems, and patient selection will be critical for maximizing therapeutic benefit while minimizing risks. As the field matures, RNA editing is poised to become a central component of the evolving landscape of genomic medicine, unlocking new possibilities for patients with previously untreatable genetic diseases.